ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients

by Vandana Singh, Benzinga Editor

May 17, 2021 12:32 PM | 1 min read | Make a Comment

ImmunityBio Inc IBRX has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in locally advanced/metastatic solid tumors.
Cryopreserved m-ceNK cells combined with Anktiva will be tested in this QUILT 3.076 Phase 1 study designed to evaluate the safety in subjects.
The study consists of two cohorts, and there will be 10 participants in each cohort. Cohort 1 includes participants with newly diagnosed high-risk solid tumors who have not received prior treatment.
Cohort 2 includes participants with relapsed/refractory solid tumors who have progressive disease after receiving more than two prior therapies.
Price Action: IBRX shares are up 8.8% at 16.46 during the market session on the last check Monday.

Posted In: Biotech News Health Care FDA General Briefs Solid Tumor

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.